Health Advocacy
NEWHow WikiLeaks Is Changing The Face
Of Journalism
Jane Bryant
The One Click Group NEW
Courage Is Contagious
How To Whistleblow Safely
Julian Assange
WikiLeaks One Click Launches
Support
Dr Sarah Myhill
Campaign
By Jane Bryant Digital Economy Bill
Threatens One Click
By Jane Bryant UPDATED
March 2010
One Click
Freedom
Of Information
UK Police Harassment
In The Internet Era Barbara Loe Fisher
Interview
NVIC Conference
Style, Gonads
Brass Ovaries
By Jane Bryant New Journalism
Challenging
Status Quo
By Jane Bryant
NVIC Conference
USA How The
Judicial Review
Of The CFS/ME
NICE Guidelines
Was Lost
Jane Bryant
The One Click Group The BMJ
Vaccines Propaganda
Professor
David Salisbury
And
Trimedia
Public Relations David Southall
"A Very
Dangerous Doctor"
Panorama swims
with sharks
Lisa Blakemore Brown Dr David Salisbury
Ooops!
Never Mind Me,
I'm Basil Fawlty! ONE CLICK RESPONSE
David Salisbury
Vaccine Litigation Biomedical Test
For ME/CFS Announced
Dr Sarah Myhill
MB BS The Politics
And Commerce
Of Autism
By Lisa Blakemore Brown
Psychologist Poling
Vaccine/Autism Case
Mitochondrial Disfunction
ME/CFS Patients One Click Response
NICE Guidelines One Click Report
Gibson Inquiry How To Solve A Problem Like ME/CFS:
Why The Gibson Report Has Failed Patients Realpolitik and ME
By Martin J. Walker The Consensus Report
Family Law Reform Canadian Definition of ME-CFS The Weird World of Wikipedia
By Martin J. Walker Click here to email us your opinions.
| [Previous] | [Next] |
| [Previous] | [Next] |
| Zambia Outraged - 46 Women Infected From HIV Trial | ||
 Daily Nation On The Web 12 January 2010 Kenya: Trial HIV Vaccine Leaves 46 Infected By Elias Mbao Lusaka — A failed clinical trial HIV vaccine that left 46 Zambian women infected with the virus has sparked controversy. The Microbicides Development Programme (MDP) 301 trial, which was testing if the gel PRO2000 would prevent HIV infection took place between September 2005 and 2009. It was conducted at six research centres in South Africa, Tanzania, Uganda and Zambia and 9,385 participated. From the Zambian site in Mazabuka district - about 160 kilometres South West of the capital Lusaka - 1, 332 HIV negative women were recruited but the results, which the Ministry of Health does not wish to comment on, revealed that between 46 and 50 of women that participated in the clinical trial contracted HIV despite using PRO2000 gel before sex. "Some participants did become HIV positive because the study was conducted in the normal environment," confirmed Dr Maureen Chisembele, principal investigator for Microbicides Development Programme Zambia - a subsidiary of the UK based research entity. "Women who became infected during the study were given further counselling and referred to local health services for ART (antiretroviral therapy)." The National Aids Council of Zambia (NAC), a government unit mandated to oversee HIV/Aids programme, confirmed that 50 out of the 1, 332 women that participated in the clinical trials contracted HIV. Due to the sensitivity and repercussions of the issue, the Ministry of Health has remained tight-lipped on the outcome of the trials. A vaginal microbicide is a product intended for use before sexual intercourse to reduce HIV infection and they are supposed to be used with condoms and complement other prevention strategies such as behaviour change, abstinence and other preventive methods. It should be noted that vaginal microbicide should not be used alone or replace correct and consistent use of condoms in the fight against HIV and Aids, said Dr Swebby Macha - a gynaecologist at Zambia's University Teaching Hospital (UTH) in Lusaka, the largest hospital in the country. The participants in the clinical trial were either assigned the PRO2000 gel or placebo gel (with inactive ingredient) and were instructed to apply gel about one hour before sexual intercourse. The gel contains molecules that are intended to cluster around the virus before it can penetrate the vaginal wall. To be effective, the women were counselled on safe sexual behaviour and encouraged to use condoms, which were provided free of charge. According to Dr Macha, this clinical trial found that the risk of HIV infection in women that were supplied with PRO2000 gel was not significantly different than women supplied with placebo gel. "The largest international clinical trial to date into a preventive HIV gel has found no evidence that the vaginal microbicide, PRO2000, reduces the risk of HIV infection in women," said Dr Macha, the former president of Zambia Medical Association (ZMA). Dr Macha said to date no microbicide had been proved to be effective against HIV infection. A local traditional ruler has demanded compensation for the infected women and prosecution of architects of the clinical trial. Chief Mwanachingwala of the Tonga people in Mazabuka district where the clinical trials took place said the women that took part in the trials were "poor and uneducated" and did not know the consequences of the research, which has left some of them infected. But Ministry of Health officials, speaking on anonymity basis, argued that MDP followed the laid down legal and clinical procedures, therefore, were not liable to prosecution over the outcome of clinical trials. In an explanatory statement, Dr Chisembele said that during the clinical trial, a lot of emphasis was put on the fact that it was unknown whether PRO2000 gel would work to prevent HIV. The infection of the 46 women has drawn outrage from many Zambians who are accusing MDP of using some African women as "guinea pig" because they are poor and ignorant. Zambia is among African countries hardest hit by Hiv infections with prevalence rate of 14.3 per cent of its population estimated at about 13 million people. |
||
|
||
